ABSTRACT Coronary thrombolysis was induced by infusion of highly purified human pro-urokinase isolated from a transformed kidney cell line (ACHN) 
CORONARY THROMBOLYSIS has been widely investigated as a means to abort the evolution of acute transmural myocardial infarction. Several attempts have also been made to develop fibrin-specific thrombolytic agents that would be more effective than streptokinase and would induce less systemic fibrinolysis. Thrombolytic agents with anticipated fibrin selectivity now include human tissue-type plasminogen activator (t-PA),' acylated plasminogen-streptokinase complex) and pro-urokinase.
Pro-urokinase is a precursor of urokinase, first identified in tissue-culture media4 5 and later purified from urine, 6 plasma,' conditioned cell culture media,'-' and transformed bacteria. 1f Although the mechanism of action of pro-urokinase remains to be established, recent reports have provided evidence that it can indeed induce more clot-selective thrombolysis in animal preparations than urokinase. " '' In this study we used a well-characterized preparation for the study of thrombolysis after coronary occlusion in dogs4 to evaluate the relative fibrinolytic effects of pro-urokinase as compared with urokinase.
Methods
Thirteen dogs weighing approximately 20 kg were anesthetized with 10 to 15 mg/kg sodium pentobarbital and artificially ventilated. Coronary thrombosis was induced by advancing a 3 to 5 mm long copper coil attached to an intracoronary catheter via the carotid artery 3 to 5 cm into the left anterior descending coronary artery distal to the first main diagonal branch, as previously described. 14 An occlusive thrombus formed within 5 to 10 min and was confirmed angiographically in all dogs. All of the animals studied developed electrocardiographic signs typical of ischemia. One hour after induction of the coronary thrombus, pro-urokinase or urokinase was infused via a peripheral vein at a rate of 10 ,ug/kg/min for 30 min. Whenever complete thrombolysis had not occurred after 30 min of infusion, the agents were administered immediately thereafter at the same rate but via the intracoronary route for an additional 15 To measure the turnover rate of pro-urokinase and the extent of systemic activation of the fibrinolytic system, blood samples were collected in citrate before and 2, 5, 10, 20, and 30 min after the onset of intravenous infusion, at the end of intracoronary infusion if one was administered, and at 2, 5, 10, 20, 30, 40, and 50 min after completion of the infusion of thrombolytic agents. Samples were cooled immediately on ice and centrifuged for immediate analysis of fibrinogen and a,-antiplasmin activity, as described previously.'4 Circulating levels of prourokinase were measured on frozen plasma samples by a classic radioimmunoassay with a rabbit antibody against human urinary urokinase. Titration curves of urokinase and pro-urokinase with this antibody were superimposable.
Pro-urokinase, highly purified from a transformed human kidney cell line (ACHN), was provided by Mochida Chemical Co. The material migrated as a single band (over 90% homogeneity) with Mr 54,000 on sodium dodecyl sulfate gel electrophoresis. The material could be fully activated by plasmin and displayed a specific activity of 95,000 /lmg protein as measured on fibrin plates. The pro-urokinase preparation used in this study contained approximately 5% of activated molecules as measured by amidolytic assay. The pharmacokinetics of pro-urokinase after its intravenous infusion at a rate of 20 gtg/kg/min for 30 min, as measured by radloimmunoassay, are summarized in figure 3 . A gradual increase of the plasma level was observed to reach a plateau level of 3.5 ,ig/ml.
After the end of the infusion, the pro-urokinase antigen disappeared from plasma with an initial tl/¼ of 7 min, but the disappearance curve was not monotone. In contrast to the measured plasma levels of prourokinase for which dilution curves were uniformly linear, those for samples containing urokinase were nonlinear when serially diluted. This observation was unexpected in view of the identical titers of the antibody to each agent as measured in buffer systems and must reflect interference with the measurement of urokinase by plasma factors such as antiproteinases, 
Discussion
The results of this study indicate that pro-urokinase, when administered intravenously at a sufficiently high rate (20 gg/kg/min), can cause dissolution of occlusive coronary clots in dogs without systemic fibrinolytic activation. Urokinase, although causing coronary thrombolysis with at least equal potency, does so only in the presence of significant systemic fibrinolysis as reflected by decreased levels of fibrinogen and a2-antiplastnin. This confirms and extends previous observations that natural3' 11 and recombinant'3 pro-urokinase cause thrombolysis with increased fibrin specificity relative to their two-chain counterparts. Our observation that urokinase effects thrombolysis at relatively similar doses as pro-urokinase is contrary to those of previous studies.3"' The reason is not readily apparent, although all of these previous reports used preparations of venous thrombosis, while we have made the first comparison between pro-urokinase and urokinase in arterial thrombosis.
Although t-PA was not used directly in this study, our preparation of coronary thrombolysis has been applied previously to the study of fibrinolysis induced by recombinant t-PA. Coronary reperfusion was achieved regularly within 13.7 ± 1.9 min without systemic fibrinolysis by an infusion of 10 gg/kg/min t-PA with control values from urokinase comparable to those obtained in this study. Although clearly not a controlled comparison, it would nonetheless appear that the specific thrombolytic activity of t-PA is at least twofold higher than that of pro-urokinase. Similar results were noted in a controlled comparison between the two in rabbits with jugular vein thrombosis,' although the rabbit is a relatively urokinase-resistant species and might constitute a less-than-optimal animal preparation for such a comparison.
Pro-urokinase is rapidly removed from the circulation, with a postinfusion tl/2 in plasma of 7 min. This clearance rate is comparable to that of t-PA in dogs, which has a tl/½ of 5 min. 1 ' The clearance rate of prourokinase is also comparable with that of urokinase in man (t'/2 16 min), '6 considering the inverse relationship between body weight and turnover. The similar turnover rate of recombinant pro-urokinase and active urokinase was also established in rabbits. ' response to thrombolytic agents, the results obtained in dogs cannot as such be extrapolated to man. Using a system composed of a radioactive plasma clot immersed in plasma,' we have previously confirmed this large interspecies variability but have observed comparable relative thrombolytic effects of t-PA, pro-urokinase, and urokinase within the same species. On the basis of the finding that the fibrinolytic system of man is more responsive to activation by t-PA and urokinase than that of most other mammalian species, it may be anticipated that the human fibrinolytic system may be more responsive to pro-urokinase than that of the dog.
In conclusion, this study confirms the results of previous reports that natural and recombinant pro-urokinase are more clot-selective thrombolytic agents than active urokinase in animals with venous thrombosis. We have now extended this observation to an experimental preparation of arterial thrombosis, which may be relevant for acute myocardial infarction. Whether pro-urokinase might constitute an alternative to t-PA for coronary thrombolysis in man remains to be further investigated.
